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Novel antibacterial oxazolidinones bearing pyrrolidinone ring system at the C-5 side chain were synthesized
and their in vitro antibacterial activities were evaluated. Most of the synthesized oxazolidinones showed good
antibacterial activity against the Gram-positive and Gram-negative bacteria tested.
Key Words : Pyrrolidinone, Oxazolidinone, Antimicrobial activity
Introduction
Because of deficiency in innovative advance in the anti-
bacterial drug development, the increasing incidence and
prevalence of bacterial resistance to clinically useful anti-
biotics is one of the most serious global health threats of the
last two decades.1-4 Oxazolidinones are a new class of anti-
bacterial agents used to overcome the innovation deficiency.
Linezolid (Figure 1) is the first oxazolidinone antibiotics
approved in 2000 for the treatment of Gram-positive bacterial
infections in humans.5 It exhibits consistent activity against
multi-resistant gram-positive pathogens including methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococci (VRE) and penicillin-resistant Streptococcus
pneumouniae.6,7 Furthermore, oxazolidinone class antibiotics
show good activity against multidrug resistance Mycobacterium
tuberculosis infections which is one of the most threatening
and wide spreading infectious disease.8-10
Linezolid is known to inhibit bacterial protein synthesis by
binding to 50S ribosomal subunit at the translation step and
prevent the formation of 70S complex, and the binding
mode was confirmed by X-ray crystallography.11
Linezolid is widely used in clinical care as a synthetic
unnatural antibiotics and is now prescribed as a last resort
antibiotics for the treatment of multi-resistant pathogens like
vancomycin, however, clinical emergences of linezolid re-
sistant bacteria including Staphylococci and Enterococci
have been reported.12-14 The most common mechanism of
linezolid resistance is point mutations in the 23S rRNA
peptidyl transferase region,15-18 and recently a new resistance
mechanism mediated by cfr gene encoding methyltransfer-
ase has been reported.19,20 Thus, there is a significant need
for the development of new oxazolidinone series with an
improved potency and spectrum of antibacterial activity.
Four types of chemical modifications of linezolid and
oxazolidinone-type antibiotics have been reported,21-24
including modifications on each of the A, B and C-rings as
well as the C-5 side chain of the A-ring substructure.22,25
Among them, recently, torezolid25 and radezolid27 as shown
in Figure 1 are under clinical development.
Oxazolidinones containing a lactam substituent represent-
ed not only antibacterial agents28,29 but also antithrombotic
Figure 1
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agents. Rivaroxaban, a lactam substituted oxazolidinone
marketed as Xarelto, is orally active and highly potent
coagulation factor Xa inhibitors and has been approved in
United States recently for the prophylaxis of venous
thromboembolism (VTE).30
Herein we report the synthesis and biological evaluation
of a series of oxazolidinone-type antibiotics in which the C-
ring has been modified by substituted pyrrolidinone ring as
shown in Figure 2. Both acetamide and triazole are used as a
C-5 side chain. The resulting compounds were then screened
against Gram-positive, Gram-negative bacteria, and also
Mycobacterium tuberculosis (Mtb) H37Rv.
Experimental Section
General. 1H and 13C-NMR spectra were recorded on
Bruker DPX 300 MHz spectrophotometer using CDCl3,
CD3OD, DMSO-d6 as NMR solvent. TMS was used as an
internal standard and chemical shift data are reported in parts
per million (ppm) and s, d, t, and m are designated as singlet,
doublet, triplet and multiplet respectively. Coupling con-
stants (J) were reported in hertz (Hz). Mass spectra were
recorded on Waters Acquity UPLC/Synapt G2 QTOF MS
mass spectrometer. The reaction progress was monitored by
thin layer chromatography (TLC). 
(S)-N-(4-(5-(Acetamidomethyl)-2-oxo-oxazolidin-3-yl)-
2-fluorophenyl)-4-chlorobutanamide (2a). Sodium carbo-
nate (87 mg, 0.89 mmol) was added to the solution of aniline
1a (20 mg, 0.74 mmol) in acetone at room temperature. 4-
Chlorobutyryl chloride (0.10 mL, 0.89 mmol) was added to
the mixture slowly. Reaction mixture was stirred at the same
temperature for 5 h and concentrated. Water (5 mL) was
added and the mixture was extracted with CH2Cl2 (10 mL ×
2). The combined organic layers were dried over MgSO4 and
concentrated under reduced pressure. The residue was puri-
fied by flash chromatography on silica gel (hexane/EtOAc,
10:1) to yield amide 2a (24 mg, 86%): 1H MMR (DMSO-d6,
300 MHz) δ 9.52 (s, 1H), 8.02 (t, J = 5.5 Hz, 1H), 7.56 (t, J =
8.9 Hz, 1H), 7.34 (dd, J = 13.3, 2.3 Hz, 1H), 6.98 (m, 1H),
4.50 (m, 1H), 3.88 (t, J = 8.9 Hz, 1 H), 3.50 (m, 3H), 3.19 (t,
J = 5.4 Hz, 2H), 2.39 (t, J = 5.4 Hz, 2H ), 1.82 (m, 2H), 1.61
(s, 3H).
(S)-N-((3-(3-Fluoro-4-(2-oxo-pyrrolidin-1-yl)phenyl)-2-
oxo-oxazolidin-5-yl)methyl)acetamide (3a). Amide 2a
(200 mg, 0.54 mmol) was dissolved in ethanol (5 mL) and
potassium hydroxide (45.4 mg, 0.81 mmol) was added.
Reaction mixture was stirred at room temperature for 3 h.
Solvent was concentrated, and the mixture was extracted
with chloroform (10 mL × 2). The combined organic layers
were washed with brine, dried over MgSO4 and concen-
trated under reduced pressure. The residue was purified by
flash chromatography on silica gel (CHCl3/MeOH, 10:1) to
yield lactam 3a (110 mg, 63%): 1H MMR (DMSO-d6, 300
MHz) δ 8.29 (t, J = 5.6 Hz, 1H), 7.65-7.36 (m, 3H), 4.81 (m,
1H), 4.19 (t, J = 9.3 Hz, 1H), 3.78 (m, 3H), 3.48 (t, J = 5.4
Hz, 2H), 2.50 (t, J = 8.2 Hz, 2H), 2.22 (m, 2H), 1.89 (s, 3H).
N-(4-((S)-5-(Acetamidomethyl)-2-oxo-oxazolidin-3-yl)-
2-fluorophenyl)-2-(benzyloxy)-4-hydroxybutanamide (6a).
Intermediate 1a (3.3 g, 12.2 mmol) was dissolved in CH2Cl2
(35 mL) at room temperature and 1 M solution of dimethyl-
aluminium chloride in hexane (29.2 mL, 14.4 mmol) was
added. The mixture was stirred till the solution was trans-
parent. 3-(Benzyloxy)dihydrofuran-2(3H)-one 5 (2.81 g,
14.64 mmol) was added to the reaction mixture and was
stirred for 4 h at the same temperature. Phosphate buffer (pH
7, 20 mL) was added to the reaction mixture, and the
mixture was extracted with CH2Cl2 (20 mL × 2). The com-
bined organic layers were dried over MgSO4 and concen-
trated under reduced pressure. The residue was purified by
flash chromatography on silica gel (CH2Cl2/MeOH, 25:1) to
afford amide 6a (4.48 g, 79%) as white solid: 1H NMR
(CD3OD, 300 MHz) δ 7.89 (t, J = 8.8 Hz, 1H), 7.68 (dd, J =
13.7, 2.7 Hz, 1H), 7.40 (m, 6H), 4.84 (m, 1H), 4.74 (d, J =
11.6 Hz, 1H), 4.66 (d, J = 11.6 Hz, 1H), 4.20 (m, 2H), 3.86
(dd, J = 9.0, 6.3 Hz, 1H), 3.77 (t, J = 6.3 Hz, 2H), 3.60 (d, J
= 5.1 Hz, 2H), 2.05 (m, 2H), 1.99 (s, 3H).
N-(((5S)-3-(4-(3-(Benzyloxy)-2-oxo-pyrrolidin-1-yl)-3-
fluorophenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (7a).
Compound 6a (3.7 g, 8.3 mmol) and triphenyl phosphine
(2.6 g, 9.8 mmol) were dissolved in CH2Cl2 (100 mL) and
diethyl azodicarboxylate (1.7 g, 9.8 mmol) was added
slowly for 20 min at ice bath temperature. The reaction
mixture was stirred at room temperature for 4 h. Water (20
mL) was added and the mixture was extracted with CH2Cl2
(100 mL × 2). The combined organic layers were dried over
MgSO4 and concentrated under reduced pressure. The
residue was purified by flash chromatography on silica gel
(CH2Cl2/MeOH, 25:1) to yield lactam 7a (2.98 g, 84%): 
1H
NMR (DMSO-d6, 300 MHz) δ 8.28 (t, J = 5.7 Hz, 1H), 7.61
(dd, J = 13.2, 2.1 Hz, 1H), 7.50 (t, J = 8.7 Hz, 1H), 7.35 (m,
6H), 4.87 (part A of AB, J = 11.9 Hz, 1H), 4.71 (part B of
AB, J = 11.9 Hz, 1H), 4.76 (m, 1H), 4.33 (t, J = 7.6 Hz, 1H),
4.15 (t, J = 8.9 Hz, 1H), 3.76 (dd, J = 8.7, 6.6 Hz, 1H), 3.70
(dd, J = 7.9, 5.3 Hz, 1H), 3.43 (t, J = 5.2 Hz, 2H), 2.5 (m,
1H), 2.08 (m, 1H), 1.85 (s, 3H).
N-(((5S)-3-(3-Fluoro-4-(3-hydroxy-2-oxo-pyrrolidin-1-
yl)phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (8a).
Benzyl ether 7a (1.0 g, 2.26 mmol) was dissolved in ethyl
alcohol (50 mL), and palladium hydroxide in activated
charcoal (0.16 g, 5 mol %) and cyclohexene (10 mL) were
added. Reaction mixture was refluxed for 3 d, cooled to
room temperature and filtered through celite. The filtrate
was concentrated and the residue was purified by flash
chromatography on silica gel (CH2Cl2/MeOH, 10:1) to yield
alcohol 8a (0.73 g, 92%): 1H NMR (DMSO-d6, 300 MHz) δ
8.28 (t, J = 5.8 Hz, 1H), 7.57 (dd, J = 13.3, 2.6 Hz, 1H), 7.48
(t, J = 8.7 Hz, 1H), 7.36 (dd, J = 8.7, 2.1 Hz, 1H), 4.76 (m,
1H), 4.32 (m, 1H), 4.12 (t, J = 9.1 Hz, 1H), 3.76 (dd, J = 8.7,
Figure 2
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6.6 Hz, 1H), 3.65 (dd, J = 10.7, 4.1 Hz, 1H), 3.44 (t, J = 5.2
Hz, 2H), 2.43 (m, 1H), 1.92 (m, 1H), 1.85 (s, 3H); HRMS





solution of diethylaminosulfur trifluoride (60 µL) in CH2Cl2
(2 mL) was added dropwise to a solution of alcohol 8a (120
mg, 0.34 mmol) in CH2Cl2 (12 mL) at −78 
oC. The reaction
mixture was warmed to room temperature gradually and
stirred for 24 h. Saturated aqueous NaHCO3 (5 mL) was
added and the mixture was extracted with CH2Cl2 (12 mL ×
2). The combined organic layers were dried over MgSO4 and
concentrated under reduced pressure. The residue was puri-
fied by flash chromatography on silica gel (CH2Cl2/MeOH,
15:1) to yield fluoride 9a (24 mg, 20%): 1H NMR (DMSO-
d6, 300 MHz) δ 7.63 (dd, J = 13.2, 2.1 Hz, 1H), 7.51 (t, J =
8.9 Hz, 1H), 7.38 (dd, J = 9.1, 2.0 Hz, 1H), 4.87 (dd, J = 7.7,
5.5 Hz, 1H), 4.76 (m, 1H), 4.16 (t, J = 8.7 Hz, 1H), 3.77 (m,
3H), 3.43 (d, J = 5.1 Hz, 1H), 2.79 (m 1H), 2.30 (m, 1H),
1.85 (s, 1H), 1.83 (s, 3H).
N-(((5S)-3-(4-(3-Chloro-2-oxo-pyrrolidin-1-yl)-3-fluoro-
phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (10a).
Thionyl chloride (60 µL) was added dropwise to a solution
of alcohol 8a (120 mg, 0.34 mmol) in acetonitrile (8 mL) at
room temperature. The reaction mixture was refluxed for 24
h, cooled to room temperature and concentrated under
reduced pressure. The residue was purified by flash chromato-
graphy on silica gel (CH2Cl2/MeOH, 10:1) to yield chloride
10b (70.6 mg, 56%): 1H NMR (CD3OD, 300 MHz) δ 7.71
(dd, J = 13.2, 3.0 Hz, 1H), 7.48 (t, J = 8.5 Hz, 1H), 7.39 (dd,
J = 8.9, 1.6 Hz, 1H), 4.84(m, 1H), 4.74 (dd, J = 7.7, 5.0 Hz,
1H), 4.20 (t, J = 9.0 Hz, 1H), 3.96 (m, 1H), 3.87 (m, 2H),
3.60 (d, J = 4.8 Hz, 2H), 2.85 (m, 1H), 2.42 (m, 1H), 2.00 (s,




phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide (11a).
Triphenylphosphine (194 mg, 0.74 mmol) and carbon tetra-
bromide (245 mg, 0.74 mmol) were added to a solution of
alcohol 8a (120 mg, 0.34 mmol) in acetonitrile (8 mL) at
room temperature. The reaction mixture was refluxed for 24
h and concentrated under reduced pressure. The residue was
purified by flash chromatography on silica gel (CH2Cl2/
MeOH, 10:1) to yield bromide 11a (45 mg, 32%): 
1H NMR (DMSO-d6, 300 MHz) δ 8.27 (t, J = 5.7 Hz, 1H),
7.64 (dd, J = 16.0, 4.9 Hz, 1H), 7.51 (t, J = 8.4 Hz, 1H), 7.39
(dd, J = 8.9, 1.6 Hz, 1H), 4.88 (m, 1H), 4.77 (m, 1H), 4.16 (t,
J = 9.0 Hz, 1H), 3.88 (m, 1H), 3.77 (m, 2H), 3.44 (d, J = 5.1
Hz, 2H), 2.83 (m, 1H), 2.38 (m, 1H), 1.85 (s, 3H); HRMS





Silver oxide (95 mg, 0.4 mmol) and methyl iodide (42 μL,
2.0 equiv) were added to a solution of alcohol 8a (120 mg,
0.34 mmol) in CH2Cl2 (8 mL), and stirred for 1.5 h at room
temperature. The reaction mixture was filtered through celite
and the filtrate was concentrated. The residue was purified
by flash chromatography on silica gel (CH2Cl2/MeOH, 20:1)
to yield methyl ether 12a (37 mg, 30%): 1H NMR (CD3OD,
300 MHz) δ 7.7 (dd, J = 13.2, 2.4 Hz, 1H), 7.46 (t, J = 8.6
Hz, 1H), 7.37 (dd, J = 8.7, 2. 7 Hz, 1H), 4.85 (m, 1H), 4.22
(m, 2H), 3.86 (dd, J = 9.3, 6.6 Hz, 1H), 3.79 (dd, J = 8.2, 5.0
Hz, 2H), 3.60 (s, 3H), 3.44 (d, J = 5.1 Hz, 2H), 2.62 (m, 1H),
2.14 (m, 1H), 2.0 (s, 3H).
N-[[(5S)-3-[4-(3-Carboxy-2-oxo-1-pyrrolidinyl)-3-Fluoro-
phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide (14a).
To a solution of aniline 1a (1.0 g, 3.7 mmol) in toluene (20
mL), 6,6-dimethyl-5,7-dioxaspiro [2.5] octane-4,8-dione
(0.95 g, 5.6 mmol) was added, and the reaction mixture was
refluxed for 24 h. The reaction mixture was cooled and
concentrated. The residue was purified by flash chromato-
graphy on silica gel (CH2Cl2/MeOH, 20:1) to yield carbox-
ylic acid 14a (1.2 g, 86%): 1H NMR (CD3OD, 300 MHz) δ
7.68 (dd, J = 13.2, 2.7 Hz, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.36
(dd, J = 9.3, 2.7 Hz, 1H), 4.83 (m, 1H), 4.20 (t, J = 9.0 Hz,
2H), 3.86 (t, J = 7.4 Hz, 2H), 3.60 (d, J = 4.8 Hz, 2H), 2.59
(t, J = 7.9 Hz, 1H), 2.27 (m, 2H), 2.00 (s, 3H).
N-(4-((S)-5-(Acetamidomethyl)-2-oxo-oxazolidin-3-yl)-
2-fluorophenyl)-3-(benzyloxy)-4-hydroxybutanamide (17a).
Compound 17a was prepared from 1a and 16 according to
the similar procedure for the preparation of compound 6a
(yield 49%): 1H NMR (DMSO-d6, 300 MHz) δ 9.76 (s, 1H),
8.28 (t, J = 5.6 Hz, 1H), 7.80 (t, J = 8.8 Hz, 1H), 7.59 (dd, J
= 13.2, 2.7 Hz, 1H), 7.27 (m, 5H), 4.82 (t, J = 5.5 Hz, 1H),
4.74 (m, 1H), 4.64 ( d, J = 12.0 Hz, 1H), 4.54 ( d, J = 12.0
Hz, 1H), 3.91 (m, 1H), 3.74 (dd, J=8.7, 6.6 Hz, 1H), 3.52 (t,




(18a). Compound 18a was prepared from 17a according to
the similar procedure for the preparation of compound 7a
(yield 99%): 1H NMR (DMSO-d6, 300 MHz) δ 8.25 (t, J =
5.6 Hz, 1H), 7.58 (dd, J = 13.2, 2.2 Hz, 1H), 7.45 (t, J = 8.7
Hz, 1H), 7.33 (m, 6H), 4.74 (m, 1H), 4.56 (s, 2H), 4.35 (m,
1H), 4.12 (t, J = 9.1 Hz, 1H), 4.03 (m, 1H), 3.75 (m, 2H),
3.42 (t, J = 5.5 Hz, 2H), 2.82 (dd, J = 17.3, 6.5 Hz, 1H), 2.49
(m, 1H), 1.83 (s, 3H).
N-(((S)-3-(3-Fluoro-4-((S)-4-hydroxy-2-oxo-pyrrolidin-
1-yl)phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (19a).
Compound 19a was prepared 18a according to the similar
procedure for the preparation of compound 8a (yield 73%):
1H NMR (DMSO-d6, 300 MHz) δ 8.27 (t, J = 5.7 Hz, 1H),
7.59 (dd, J = 13.2, 2.4 Hz, 1H), 7.47 (t, J = 8.9 Hz, 1H), 7.35
(dd, J = 8.7, 2.7 Hz, 1H), 4.76 (m, 1H), 4.44 (m, 1H), 4.15 (t,
J = 9.0 Hz, 1H), 4.00 (dd, J = 9.9, 5.1 Hz, 1H), 3.76 (dd, J =
9.0, 6.3 Hz, 1H), 3.50 (dd, J = 9.9, 1.8 Hz, 1H), 3.44 (t, J =
5.6 Hz, 2H), 2.76 (dd, J = 17.1, 6.6 Hz, 1H), 2.25 (dd, J =
16.7, 2.5 Hz, 1H), 1.85 (s, 1H), 1.83 (s, 3H); HRMS (EI+)
calcd for C16H18FN3NaO5 (M+): 374.1128, found: 374.1302.
N-(((S)-3-(3-Fluoro-4-((S)-4-fluoro-2-oxo-pyrrolidin-1-
yl)phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (20a).
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Compound 20a was prepared 19a according to the similar
procedure for the preparation of compound 9a (yield 33%):
1H NMR (CD3OD, 300 MHz) δ 7.61 (dd, J = 13.2, 2.4 Hz,
1H), 7.46 (t, J = 12.6 Hz, 1H), 7.35 (dd, J = 8.9, 2.3 Hz, 1H),
4.81 (m, 1H), 4.42 (dd, J = 11.6, 5.0 Hz, 1H), 4.20 (t, J = 9.1
Hz, 2H), 3.91 (m, 1H), 3.87 (dd, J = 9.0, 6.3 Hz, 1H), 3.50
(d, J = 4.8 Hz, 2H), 3.26 (dd, J = 17.4, 6.6 Hz, 1H), 2.74 (dd,
J = 16.4, 3.5 Hz, 1H), 2.0 (s, 3H). 
N-(((S)-3-(4-((S)-4-Chloro-2-oxo-pyrrolidin-1-yl)-3-fluoro-
phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (21a).
Compound 21a was prepared from 19a according to the
similar procedure for the preparation of compound 10a
(yield 56%): 1H NMR (CD3OD, 300 MHz) δ 7.71 (dd, J =
13.2, 2.4 Hz, 1H), 7.47 (t, J = 12.6 Hz, 1H), 7.38 (dd, J =
8.9, 2.3 Hz, 1H), 4.86 (m, 1H), 4.42 (dd, J = 11.6, 5.0 Hz,
1H), 4.20 (t, J = 9.1 Hz, 2H), 3.92 (m, 1H), 3.87 (dd, J = 9.0,
6.3 Hz, 1H), 3.60 (d, J = 4.8 Hz, 2H), 3.26 (dd, J = 17.4, 6.6
Hz, 1H), 2.74 (dd, J = 16.4, 3.5 Hz, 1H), 2.0 (s, 3H). 
N-(((5S)-3-(4-(4-Bromo-2-oxo-pyrrolidin-1-yl)-3-fluoro-
phenyl)-2-oxo-oxazolidin-5-yl)methyl)acetamide (22a).
Compound 22a was prepared from 19a according to the
similar procedure for the preparation of compound 11a
(yield 80%): 1H NMR (CD3OD, 300 MHz) δ 7.71 (dd, J =
12.9, 2.7 Hz, 1H), 7.48 (t, J = 8.5 Hz, 1H), 7.38 (dd, J = 9.4,
2.3 Hz, 1H), 4.85 (m, 1H), 4.48 (dd, J = 11.8, 5.2 Hz, 1H),
4.20 (t, J = 9.1 Hz, 2H), 4.02 (dd, J = 11.7, 1.8 Hz, 1H), 3.87
(dd, J = 9.0, 6.3 Hz, 1H), 3.63 (d, J = 4.8 Hz, 2H), 3.34 (m,
1H), 2.86 (dd, J = 17.7, 2.1 Hz, 1H), 2.00 (s, 3H); HRMS





Compound 23a was prepared from 19a according to the
similar procedure for the preparation of compound 12a
(yield 42%): 1H NMR (CD3OD, 300 MHz) δ 7.68 (dd, J =
13.1, 2.6 Hz, 1H), 7.44 (t, J = 8.4 Hz, 1H), 7.35 (dd, J = 8.8,
2.8 Hz, 1H), 5.53 (s, 1H), 4.82 (m, 1H), 4.22 (m, 1H), 4.12
(m, 2H), 3.82 (m, 2H), 3.59 (d, J = 4.8 Hz, 2H), 3.42 (s, 3H),
2.90 (dd, J = 17.4, 6.3 Hz, 1H), 2.56 (dd, J = 17.6, 2.3 Hz,
1H), 2.00 (s, 3H).
Biological Assay. 
MIC (Minimal Inhibitory Concentrations) Determina-
tion: Minimal inhibitory concentrations (MICs) were deter-
mined by two-fold agar dilution as described by the Clinical
and Laboratory Standards Institute.31 Test strains were
grown for 18 h at 37 °C in tryptic soy broth and diluted with
the same fresh medium to a density of ca. 107 colony form-
ing units (CFU)/mL. Suspensions were applied to Mueller-
Hinton agar (MHA) plates containing serial dilutions of
antimicrobial agents using a multipoint inoculator to yield
105 CFU/spot. Plates were incubated in air at 37 °C for 18 h
and were examined for growth. The MIC was considered to
be the lowest concentration that completely inhibited growth
on agar plates, disregarding a single colony or a faint haze
caused by the inoculum.
MIC (Minimal Inhibitory Concentrations) Determina-
tion of Mycobacterium tuberculosis: The MICs of compounds
against Mycobacterium tuberculosis (Mtb) H37Rv was deter-
mined by the Microplate Alamar Blue Assay.32 
Results and Discussion
Chemistry. Two types of oxazolidinone starting material,
acetamide 1a and 1,2,3-triazole 1b, were synthesized by
modification of literature method.33,34 Oxazolidinone deriva-
tives having pyrrolidinone at the C-ring were prepared by
coupling of amino group in 1a and 1b with 4-chlorobutyryl
chloride and the subsequent cyclization to form pyrrolidone
in good yields as shown in Scheme 1.
α-Hydroxy pyrrolidinonyl oxazolidinone 8a and 8b were
also prepared by the condensation of amino group in 1a and
1b with 3-(benzyloxy)dihydrofuran-2(3H)-one and followed
by intramolecular Mitsunobu-type cyclization and sub-
sequent hydrogenation protocol as shown in Scheme 2. α-
Hydroxy pyrrolidinone 8a was obtained as inseparable dia-
stereomeric mixture, and one of its single diastereomer was
prepared by using optically active 3(R)-3-(benzyloxy)di-
hydrofuran-2(3H)-one. The synthesis of other oxazolidinone
derivatives having α-substituted pyrrolidinones at C-ring of
linezolid was shown in Scheme 2 too. Halogenation of
alcohol 8a and 8b gave the fluoride, chloride and bromide
compounds 9-11 by using diethylaminosulfur trifluoride
(DAST), thionyl chloride and triphenylphosphine with
carbon tetrabromide respectively in moderate to good yields.
O-Methylation of α-hydroxy compound 8a with methyl
iodide in the presence of silver oxide provided α-methoxy
compound 12a.
N-Aryl-2-oxo-pyrrolidine-3-carboxylic acid 14a were
synthesized by the reaction of arylamine 1a and 6,6-di-
methyl-5,7-dioxaspiro[2.5]octane-4,8-dione 13 in toluene at
Scheme 1. i) Na2CO3, acetone, rt, 5 h, 86% (2a), 85% (2b); ii) KOH, EtOH, rt, 3 h, 63% (3a), 68% (3b).
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reflux condition in good yield as shown in Scheme 3. 
3-Substituted-2-oxo-pyrrolidinyl oxazolidinone deriva-
tives 18-23 were synthesized from 4-hydroxydihydrofuran-
2(3H)-one 15 following the similar synthetic procedure of
the corresponding α-substituted compounds 7-12 as shown
in Scheme 4.
Biological Evaluation. This series of oxazolidinone anti-
microbial compounds prepared above were screened against
panel of susceptible and resistance bacteria. MICs (µg/mL)
of these compounds against standard strains were summarized
in Table 1 and linezolid was used as a reference compound
for comparison. The compounds were also tested against
drug-resistant strains such as MRSA, VRE (vancomycin-
resistant Enterococcus faecium), Coagulase negative Staph-
ylococi, E. faecalis, and S. pneumonia, and the results were
shown in Table 2. 
Most of the prepared oxazolidinone derivatives having
pyrrolidinone moiety exhibited good activity against the
tested Gram-positive and Gram-negative bacteria (Table 1
and Table 2). The new pyrrolidone compounds bearing
acetamide at position C-5 were more active than those with
1,2,3-triazole at the same position, and the α-substituted
pyrrolidinone compounds were more active than the corre-
sponding α-substituted compounds.
Among C-5 acetamide-substituted oxazolidinones, pyrro-
lidinone compound 3a had comparable activity with the
reference compound linezolid but α-hydroxy substituted
pyrrolidinone compound 8a lost the activity. In case of 8a,
both single isomer and diastereomeric mixture exhibited
similar antibacterial activity against most tested strains.
However oxazolidinones with halogenated pyrrolidinone
moiety at α- or β-position (9a-11a, 20a-22a) showed com-
Scheme 2. (i) Ag2O, BnBr, MC, rt, 10 h, 60%; (ii) 1a or 1b, Me2AlCl, DCM, rt, 5 h, 79% (6a), 70% (6b); (iii) PPh3, DEAD, DCM, rt, 5 h,
84% (7a), 85% (7b); (iv) Pd(OH)2/C, cyclohexene, EtOH, reflux, 3 d, 92% (8a), 75% (8b); (v) Et2NSF3, DCM, −78 
oC to rt, 24 h, 20%
(9a), 43% (9b); (vi) SOCl2, MeCN, rt to reflux, 24 h, 56% (10a), 46% (10b); (vii) PPh3, CBr4, MeCN, reflux, 24 h, 32% (11a); (viii) CH3I,
Ag2O, MC, rt, 1.5 h, 30% (12a).
Scheme 3. (i) toluene, reflux, 24 h, 86%.
Scheme 4. (i) Ag2O, BnBr, DCM, rt, 10 h, 60%; (ii) 1a or 1b, Me2AlCl, DCM, rt, 5 h, 49% (17a), 65% (17b); (iii) PPh3, DEAD, DCM, rt,
5 h, 99% (18a), 83% (18b); (iv) Pd(OH)2/C, cyclohexene, EtOH, reflux, 3 d, 73% (19a), 80% (19b); (v) Et2NSF3, DCM, −78
oC to rt, 24 h,
33% (20a), 40% (20b); (vi) SOCl2, MeCN, rt to reflux, 24 h, 56% (21a), 48% (21b); (vii) PPh3, CBr4, MeCN, reflux, 24 h, 80% (22a);
(viii) CH3I, Ag2O, DCM, rt, 1.5 h, 42% (23a).
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parable antibacterial activities against most tested bacteria
including resistant strains with the linezolid. Substitution of
methoxy and carboxylic group at α-position of pyrrolidone
(12a, 14a) lost the activity slightly, and β-hydroxy compounds
19a completely lost the activity.
Among C-5 1,2,3-triazole oxazolidinones, pyrrolidinone
compound 3b was less active than reference compound, and
substitution of hydroxyl group at α-position of pyrrolidinone
(8b) slightly improved the activity. Fluoride and chloride
substituted oxazolidinones at α-position of pyrrolidone (9b
and 10b) showed good antibacterial activity, and demon-
strated similar activities against most resistant strains com-
pared to linezolid. Almost β-substituted compounds at
pyrrolidinone part were less active than α-substituted com-
pounds in the 1,2,3-triazole series, and β-hydroxy compound
19b completely lost the activity. The 2-oxopyrrolidinyl
oxazolidinones of both C-5 acetamide and triazole series are
less active than linezolid against gram-negative Hameophilus
influenza.
Notably, the new oxazolidinone derivatives possessing
pyrrolidinone moiety showed comparable or higher activity
than linezolid against Mycobacterium tuberculosis (Mtb)
H37Rv as shown in Table 2. Compound 11a, 20a and 9b
showed 2-fold higher activity than linezolid against
Mycobacterium tuberculosis. 
Conclusion
A new series of oxazolidinones having 2-oxopyrrolidine
moiety have been synthesized, and their in vitro antibacterial
activities were evaluated against Gram-positive, Gram-
negative bacteria including resistant strains of Staphylococi,
Streptococci and Enterococci. Some of these analogs ex-
hibited potent in vitro antibacterial activities comparable or
superior to linezolid. The compounds exhibited potent
antibacterial activity against Mycobacterium tuberculosis
(Mtb) H37Rv, and the compound 11a, 20a and 9b showed 2-
fold higher activity than linezolid against M. tuberculosis.
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